ERRATUM

Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population

Mariano J Taverna, María T Martínez-Larrad, Gustavo D Frechtel and Manuel Serrano-Ríos

The authors and the journal apologise for errors in Table 1 of the above article published in March 2011, vol 164, pp 559–567. Some data relating to women were inadvertently omitted from the table. The clinical characteristics of the whole sample and women are published in full below.

Table 1 Clinical characteristics of the sample population.

		Women (n=416)			
	Whole sample (n=768)	MS-NCEP + (n=64)	MS-NCEP – (n=352)	MS-IDF + (n=73)	MS-IDF – (n=343)
Continuous variables (mean ± s.d.)					
Age (years)	54.0 ± 11.6	61.0 ± 10.3	53.3 ± 11.3	60.7 ± 10.0	53.1 ± 11.4
BMI (kg/m ²)	27.43 ± 3.97	31.84 ± 4.04	26.48 ± 4.05	31.22 ± 4.19	26.48 ± 4.09
WC (cm)	90.12 ± 11.37	98.05 ± 8.21	83.02 ± 9.91	96.34 ± 9.00	83.02 ± 9.91
HC (cm)	100.23 ± 7.96	108.52 ± 9.20	100.19 ± 7.99	107.43 ± 9.26	100.20 ± 8.05
WHR	0.90 ± 0.10	0.90 ± 0.07	0.83 ± 0.07	0.90 ± 0.07	0.83 ± 0.07
SBP (mmHg)	124.6 ± 17.1	140.21 ± 16.99	120.82 ± 16.87	140.33 ± 16.35	120.28 ± 16.66
DBP (mmHg)	78.3 ± 8.9	85.03 ± 9.04	76.40 ± 8.35	84.62 ± 9.02	76.26 ± 8.30
FPG (mmol/l)	4.91 ± 1.16	5.76 ± 1.88	4.65 ± 0.64	5.72 ± 1.81	4.63 ± 0.61
2 h glucose (mmol/l)	6.43 ± 2.39	8.55 ± 3.00	6.04 ± 1.94	8.49 ± 2.93	6.00 ± 1.91
Fasting insulin (μU/ml)	13.21 ± 8.65	22.38 ± 15.32	11.31 ± 6.61	21.24 ± 14.88	11.29 ± 6.65
2 h insulin (μU/ml)	76.41 ± 66.16	130.57 ± 92.67	69.42 ± 54.87	122.08 ± 90.46	69.66 ± 55.32
Fasting proinsulin (pmol/l)	10.67 ± 8.37	15.96 ± 11.18	8.45 ± 5.70	15.07 ± 10.91	8.46 ± 5.73
HOMA-IR	1.76 ± 0.95	2.70 ± 1.30	1.53 ± 0.73	2.57 ± 1.29	1.52 ± 0.73
TC (mg/dl)	213.69 ± 39.19	218.67 ± 46.08	210.49 ± 37.61	218.42 ± 47.51	210.32 ± 36.97
LDL-C (mg/dl)	133.20 ± 34.28	140.06 ± 36.18	127.64 ± 32.67	139.92 ± 36.77	127.34 ± 32.38
HDL-C (mg/dl)	60.18 ± 16.39	52.89 ± 12.71	66.64 ± 16.48	53.27 ± 13.30	66.93 ± 16.38
TG (mg/dl)	98.12 ± 60.37	128.63 ± 57.84	73.78 ± 29.59	126.18 ± 57.13	72.87 ± 28.36
TG/HDL-C ratio	1.90 ± 1.74	2.61 ± 1.40	1.21 ± 0.71	2.53 ± 1.36	1.18 ± 0.69
LAP	34.65 ± 28.74	58.79 ± 30.00	21.96 ± 14.17	55.50 ± 29.85	21.70 ± 14.07
Dichotomic variables (%)					
Sedentary	33.1	34.4	27.8	31.5	28.3
Smoking	22.7	9.4	16.5	8.2	16.9
Obesity	24.8	64.1	19.6	56.2	20.1
HW	10.8	35.9	2.6	32.9	2.3
EWETS	14.2	39.1	2.3	34.2	2.3
FPG ≥ 5.6 mmol/l	15.1	54.7	4.0	53.4	2.9
TG ≥ 150 mg/dl	13.5	31.3	1.7	30.1	1.2
Low HDL-C ^a	14.3	50.0	11.1	47.9	10.5
High BP ^b	41.7	85.9	30.9	87.7	29.1
High WC (NCEP/ATP III) ^c	32.0	98.4	30.1	86.3	30.9
High WC (IDF) ^d	63.7	100.0	51.1	100.0	58.6
MS-NCEP/ATP III	15.2	NA	NA	87.7	0.0
MS-IDF	18.9	100.0	2.6	NA	NA

BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; EWETS, enlarged waist elevated triglyceride syndrome; FPG, fasting plasma glucose; HC, hip circumference; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HW, hypertriglyceridemic waist; LAP, lipid accumulation product; LDL-C, low-density lipoprotein cholesterol; NA, non applicable; SBP, systolic blood pressure; MS-IDF, International Diabetes Federation-diagnosed metabolic syndrome; MS-NCEP/ATP III, National Cholesterol Education Program/Adult Treatment Panel III-diagnosed metabolic syndrome; TC, total cholesterol; TG, triglycerides; TG/HDL-C ratio, triglycerides-to-high-density lipoprotein cholesterol ratio; WC, waist circumference; WHR, waist-to-hip circumference.

^aHDL-C < 40 mg/dl (men) or < 50 mg/dl (women).

^bSBP ≥ 130 and/or DBP ≥ 85 mmHg or treatment of diagnosed hypertension.

^cWC > 102 cm (men) or > 88 cm (women).

^dWC ≥ 94 cm (men) or ≥ 80 cm (women).